FDA updates EUA for COVID-19 convalescent plasma
The Food and Drug Administration last week revised and reissued its emergency use authorization for COVID-19 convalescent plasma to treat hospitalized patients with COVID-19.
The changes include updates based on additional clinical trials; clarify the authorization’s limit to high-titer convalescent plasma for hospitalized patients early in the disease and those with impaired humoral immunity; and add to the tests acceptable for qualifying high-titer COVID-19 convalescent plasma.
Related News Articles
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…